Liquidia faces patent ruling risk after Yutrepia launch boosts revenue

Liquidia faces patent ruling risk after Yutrepia launch boosts revenue
Liquidia faces patent risk

Liquidia is under pressure after a patent infringement ruling against its pulmonary hypertension drug Yutrepia threatens a key growth driver. The decision comes after the product helped lift revenue sharply following its FDA approval in June 2025, raising the prospect of damages or a temporary market withdrawal.

Highlights

  • Liquidia faces possible damages and forced withdrawal of Yutrepia after a court found infringement of United Therapeutics patents for PH-ILD treatment.
  • Yutrepia drove Liquidia's turnaround from $12 million revenue and $80 million loss to $304 million revenue and $127 million profit following FDA approval in June 2025.
  • Liquidia shares fell and United Therapeutics stock rose after the ruling, reflecting market concern that Yutrepia's future sales and valuation are at risk.

Patent ruling puts Yutrepia sales at risk

As reported by Financial Times, a court ruling last Wednesday found that Liquidia infringes United Therapeutics patents covering the formulation and use of Yutrepia for treating PH-ILD. The decision exposes Liquidia to potential damages and could force the company to temporarily withdraw the drug from the market if it cannot resolve the dispute.

Yutrepia has become central to Liquidia's financial performance since its FDA approval in June 2025. In the same period this year, the company moved from $12 million in revenue and an $80 million loss to $304 million in revenue and a $127 million profit, making the drug a major commercial asset.

United Therapeutics, Liquidia's main competitor in the pulmonary hypertension market, pursued legal action after the Yutrepia launch, arguing that the product infringes patents linked to its rival therapy Tyvaso. With a court-mandated deadline approaching, Liquidia is trying to revise Yutrepia's label in an effort to keep the drug on the market and limit further legal complications.

Investor fallout and treatment access concerns

Investors reacted sharply to the ruling, sending Liquidia shares lower and lifting United Therapeutics stock as the market reassessed the competitive balance in pulmonary hypertension treatments. The market response highlights how heavily Liquidia's valuation depends on Yutrepia remaining commercially available.

Beyond the financial impact, the dispute also carries implications for patient access. Liquidia warns that a full revocation of Yutrepia's approval during the litigation would create risks for patients, as both companies continue to argue their positions while trying to protect their standing in the sector.

In our earlier coverage of shareholder pressure on Mattel, we reported that Ariel Investments urged the company to review strategic alternatives, including a potential sale, arguing the toymaker’s public valuation undervalues its underlying worth. Mattel said its board and management would consider Ariel’s views and other shareholder perspectives, raising expectations of possible major strategic shifts watched closely by investors.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.